143 related articles for article (PubMed ID: 38654089)
1. RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia.
Huynh K
Nat Rev Cardiol; 2024 Jun; 21(6):353. PubMed ID: 38654089
[No Abstract] [Full Text] [Related]
2. Aerobic exercise reduces triglycerides by targeting apolipoprotein C3 in patients with coronary heart disease.
Wang Y; Shen L; Xu D
Clin Cardiol; 2019 Jan; 42(1):56-61. PubMed ID: 30511426
[TBL] [Abstract][Full Text] [Related]
3. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.
Gouni-Berthold I
Atheroscler Suppl; 2017 Nov; 30():19-27. PubMed ID: 29096837
[TBL] [Abstract][Full Text] [Related]
4. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.
Gaudet D; Alexander VJ; Baker BF; Brisson D; Tremblay K; Singleton W; Geary RS; Hughes SG; Viney NJ; Graham MJ; Crooke RM; Witztum JL; Brunzell JD; Kastelein JJ
N Engl J Med; 2015 Jul; 373(5):438-47. PubMed ID: 26222559
[TBL] [Abstract][Full Text] [Related]
5. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
Bergmark BA; Marston NA; Prohaska TA; Alexander VJ; Zimerman A; Moura FA; Murphy SA; Goodrich EL; Zhang S; Gaudet D; Karwatowska-Prokopczuk E; Tsimikas S; Giugliano RP; Sabatine MS;
N Engl J Med; 2024 May; 390(19):1770-1780. PubMed ID: 38587249
[TBL] [Abstract][Full Text] [Related]
6. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.
Alexander VJ; Xia S; Hurh E; Hughes SG; O'Dea L; Geary RS; Witztum JL; Tsimikas S
Eur Heart J; 2019 Sep; 40(33):2785-2796. PubMed ID: 31329855
[TBL] [Abstract][Full Text] [Related]
7. Targeting APOC3 in the familial chylomicronemia syndrome.
Gaudet D; Brisson D; Tremblay K; Alexander VJ; Singleton W; Hughes SG; Geary RS; Baker BF; Graham MJ; Crooke RM; Witztum JL
N Engl J Med; 2014 Dec; 371(23):2200-6. PubMed ID: 25470695
[TBL] [Abstract][Full Text] [Related]
8. Metabolic characterisation of disturbances in the APOC3/triglyceride-rich lipoprotein pathway through sample-based recall by genotype.
Corbin LJ; Hughes DA; Chetwynd AJ; Taylor AE; Southam AD; Jankevics A; Weber RJM; Groom A; Dunn WB; Timpson NJ
Metabolomics; 2020 Jun; 16(6):69. PubMed ID: 32494907
[TBL] [Abstract][Full Text] [Related]
9. Potential options to treat hypertriglyceridaemia.
Viljoen A; Wierzbicki AS
Curr Drug Targets; 2009 Apr; 10(4):356-62. PubMed ID: 19355860
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease.
Kohan AB
Curr Opin Endocrinol Diabetes Obes; 2015 Apr; 22(2):119-25. PubMed ID: 25692924
[TBL] [Abstract][Full Text] [Related]
11. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
Schmitz J; Gouni-Berthold I
Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
Graham MJ; Lee RG; Bell TA; Fu W; Mullick AE; Alexander VJ; Singleton W; Viney N; Geary R; Su J; Baker BF; Burkey J; Crooke ST; Crooke RM
Circ Res; 2013 May; 112(11):1479-90. PubMed ID: 23542898
[TBL] [Abstract][Full Text] [Related]
13. The -1131 T>C and S19W APOA5 gene polymorphisms are associated with high levels of triglycerides and apolipoprotein C-III, but not with coronary artery disease: an angiographic study.
Martinelli N; Trabetti E; Bassi A; Girelli D; Friso S; Pizzolo F; Sandri M; Malerba G; Pignatti PF; Corrocher R; Olivieri O
Atherosclerosis; 2007 Apr; 191(2):409-17. PubMed ID: 16682041
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies.
Dib I; Khalil A; Chouaib R; El-Makhour Y; Noureddine H
Mol Biol Rep; 2021 Jan; 48(1):875-886. PubMed ID: 33389539
[TBL] [Abstract][Full Text] [Related]
15. Association of Sst I polymorphism in apolipoprotein C3 gene with hypertriglyceridaemia in coronary atherosclerotic heart disease and type II diabetes mellitus in Chinese population.
Liu HK; Li XF; Zhang SZ; Ren Y; Yong-Xin ; Liu YQ; Wang CT; Chen X; Hu YM; Zhang L
Yi Chuan Xue Bao; 2005 Jan; 32(1):11-8. PubMed ID: 15715433
[TBL] [Abstract][Full Text] [Related]
16. An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?
Chan DC; Chen MM; Ooi EM; Watts GF
Int J Clin Pract; 2008 May; 62(5):799-809. PubMed ID: 18201179
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.
Tardif JC; Karwatowska-Prokopczuk E; Amour ES; Ballantyne CM; Shapiro MD; Moriarty PM; Baum SJ; Hurh E; Bartlett VJ; Kingsbury J; Figueroa AL; Alexander VJ; Tami J; Witztum JL; Geary RS; O'Dea LSL; Tsimikas S; Gaudet D
Eur Heart J; 2022 Apr; 43(14):1401-1412. PubMed ID: 35025993
[TBL] [Abstract][Full Text] [Related]
18. Demystifying the management of hypertriglyceridaemia.
Watts GF; Ooi EM; Chan DC
Nat Rev Cardiol; 2013 Nov; 10(11):648-61. PubMed ID: 24060958
[TBL] [Abstract][Full Text] [Related]
19. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A; Glynn RJ; Fruchart JC; MacFadyen JG; Zaharris ES; Everett BM; Campbell SE; Oshima R; Amarenco P; Blom DJ; Brinton EA; Eckel RH; Elam MB; Felicio JS; Ginsberg HN; Goudev A; Ishibashi S; Joseph J; Kodama T; Koenig W; Leiter LA; Lorenzatti AJ; Mankovsky B; Marx N; Nordestgaard BG; Páll D; Ray KK; Santos RD; Soran H; Susekov A; Tendera M; Yokote K; Paynter NP; Buring JE; Libby P; Ridker PM;
N Engl J Med; 2022 Nov; 387(21):1923-1934. PubMed ID: 36342113
[TBL] [Abstract][Full Text] [Related]
20. SNPs at the APOA5 gene account for the strong association with hypertriglyceridaemia at the APOA5/A4/C3/A1 locus on chromosome 11q23 in the Northern Irish population.
Wright WT; Young IS; Nicholls DP; Patterson C; Lyttle K; Graham CA
Atherosclerosis; 2006 Apr; 185(2):353-60. PubMed ID: 16125709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
